Description: CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Home Page: www.curevac.com
Friedrich-Miescher-Strasse 15
Tübingen,
72076
Germany
Phone:
49 7071 9883 0
Officers
| Name | Title |
|---|---|
| Dr. Alexander Zehnder M.B.A., M.D. | CEO, MD & Member of Management Board |
| Dr. Malte Greune Ph.D. | COO, Member of Management Board & MD |
| Dr. Myriam Mendila M.D. | Chief Scientific Officer, Head of R&D, MD & Member of the Management Board |
| Dr. Ulrike Gnad-Vogt M.D., Ph.D. | Senior VP & Area Head of Oncology |
| Mr. Axel-Sven Malkomes | CFO & Member of Executive Board |
| Dr. Sarah Fakih | Vice President Corporate Communications & Investor Relations |
| Mr. Marco Rau L.L.M., Ph.D. | General Counsel |
| Mr. Thorsten Schuller | Head of Corporate Communications |
| Slavica Stevanovic-Heck | Head of Human Resources |
| Dr. Patrick Baumhof | Senior Vice President of Technology |
Exchange: XETRA
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 5.2329 |
|---|---|
| Trailing PE: | 6.3702 |
| Price-to-Book MRQ: | 0.9268 |
| Price-to-Sales TTM: | 10.1986 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 999 |